150 related articles for article (PubMed ID: 19205839)
1. Time-to-time correlation of high-risk atherosclerotic lesions identified with [(18)F]-FDG-PET/CT.
Wassélius J; Larsson S; Jacobsson H
Ann Nucl Med; 2009 Jan; 23(1):59-64. PubMed ID: 19205839
[TBL] [Abstract][Full Text] [Related]
2. Imaging of inflamed and vulnerable plaque in coronary arteries with 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation.
Wykrzykowska J; Lehman S; Williams G; Parker JA; Palmer MR; Varkey S; Kolodny G; Laham R
J Nucl Med; 2009 Apr; 50(4):563-8. PubMed ID: 19289431
[TBL] [Abstract][Full Text] [Related]
3. The Role of 18F-FDG PET/CT in the evaluation of Ascites of Undetermined Origin.
Zhang M; Jiang X; Zhang M; Xu H; Zhai G; Li B
J Nucl Med; 2009 Apr; 50(4):506-12. PubMed ID: 19289438
[TBL] [Abstract][Full Text] [Related]
4. Fever of unknown origin: the role of 18F-FDG PET/CT.
Keidar Z; Gurman-Balbir A; Gaitini D; Israel O
J Nucl Med; 2008 Dec; 49(12):1980-5. PubMed ID: 18997040
[TBL] [Abstract][Full Text] [Related]
5. Application of 18F-FDG PET for monitoring the therapeutic effect of antiinflammatory drugs on stabilization of vulnerable atherosclerotic plaques.
Ogawa M; Magata Y; Kato T; Hatano K; Ishino S; Mukai T; Shiomi M; Ito K; Saji H
J Nucl Med; 2006 Nov; 47(11):1845-50. PubMed ID: 17079818
[TBL] [Abstract][Full Text] [Related]
6. Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma.
Tateishi U; Hosono A; Makimoto A; Nakamoto Y; Kaneta T; Fukuda H; Murakami K; Terauchi T; Suga T; Inoue T; Kim EE
Ann Nucl Med; 2009 Feb; 23(2):155-61. PubMed ID: 19225939
[TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of CECT and 18F-FDG-PET/CT in detection of hepatic metastases.
D'souza MM; Sharma R; Mondal A; Jaimini A; Tripathi M; Saw SK; Singh D; Mishra A; Tripathi RP
Nucl Med Commun; 2009 Feb; 30(2):117-25. PubMed ID: 19057427
[TBL] [Abstract][Full Text] [Related]
8. Impact of whole-body imaging on treatment decision to radio-frequency ablation in patients with malignant liver tumors: comparison of [18F]fluorodeoxyglucose-PET/computed tomography, PET and computed tomography.
Kuehl H; Rosenbaum-Krumme S; Veit-Haibach P; Stergar H; Forsting M; Bockisch A; Antoch G
Nucl Med Commun; 2008 Jul; 29(7):599-606. PubMed ID: 18528181
[TBL] [Abstract][Full Text] [Related]
9. Quantitative assessment of the atherosclerotic burden of the aorta by combined FDG-PET and CT image analysis: a new concept.
Bural GG; Torigian DA; Chamroonrat W; Alkhawaldeh K; Houseni M; El-Haddad G; Alavi A
Nucl Med Biol; 2006 Nov; 33(8):1037-43. PubMed ID: 17127178
[TBL] [Abstract][Full Text] [Related]
10. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment.
Bastiaannet E; Wobbes T; Hoekstra OS; van der Jagt EJ; Brouwers AH; Koelemij R; de Klerk JM; Oyen WJ; Meijer S; Hoekstra HJ
J Clin Oncol; 2009 Oct; 27(28):4774-80. PubMed ID: 19720925
[TBL] [Abstract][Full Text] [Related]
11. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
De Giorgi U; Valero V; Rohren E; Dawood S; Ueno NT; Miller MC; Doyle GV; Jackson S; Andreopoulou E; Handy BC; Reuben JM; Fritsche HA; Macapinlac HA; Hortobagyi GN; Cristofanilli M
J Clin Oncol; 2009 Jul; 27(20):3303-11. PubMed ID: 19451443
[TBL] [Abstract][Full Text] [Related]
12. PET/CT for the staging and follow-up of patients with malignancies.
Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of a breath-holding acquisition method in PET/CT for pulmonary lesions.
Yamaguchi T; Ueda O; Hara H; Sakai H; Kida T; Suzuki K; Adachi S; Ishii K
Ann Nucl Med; 2009 Jan; 23(1):65-71. PubMed ID: 19205840
[TBL] [Abstract][Full Text] [Related]
14. A unique presentation of appendicitis: F-18 FDG PET/CT.
Koff SG; Sterbis JR; Davison JM; Montilla-Soler JL
Clin Nucl Med; 2006 Nov; 31(11):704-6. PubMed ID: 17053390
[TBL] [Abstract][Full Text] [Related]
15. When to image carotid plaque inflammation with FDG PET/CT.
Graebe M; Borgwardt L; Højgaard L; Sillesen H; Kjaer A
Nucl Med Commun; 2010 Sep; 31(9):773-9. PubMed ID: 20543757
[TBL] [Abstract][Full Text] [Related]
16. PET/CT for therapy response assessment in lymphoma.
Hutchings M; Barrington SF
J Nucl Med; 2009 May; 50 Suppl 1():21S-30S. PubMed ID: 19380407
[TBL] [Abstract][Full Text] [Related]
17. 18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer.
Krause BJ; Herrmann K; Wieder H; zum Büschenfelde CM
J Nucl Med; 2009 May; 50 Suppl 1():89S-96S. PubMed ID: 19380406
[TBL] [Abstract][Full Text] [Related]
18. The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries.
Schwarz JK; Grigsby PW; Dehdashti F; Delbeke D
J Nucl Med; 2009 May; 50 Suppl 1():64S-73S. PubMed ID: 19380409
[TBL] [Abstract][Full Text] [Related]
19. Desmoplastic melanoma: true positive and false negative findings on F-18 FDG-PET/CT.
Roarke MC; Nguyen BD; Pockaj BA
Clin Nucl Med; 2008 Aug; 33(8):562-4. PubMed ID: 18645380
[No Abstract] [Full Text] [Related]
20. Idiopathic pulmonary fibrosis and diffuse parenchymal lung disease: implications from initial experience with 18F-FDG PET/CT.
Groves AM; Win T; Screaton NJ; Berovic M; Endozo R; Booth H; Kayani I; Menezes LJ; Dickson JC; Ell PJ
J Nucl Med; 2009 Apr; 50(4):538-45. PubMed ID: 19289428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
